QLT sells superseded AMD therapy Visudyne to Valeant
This article was originally published in Scrip
Valeant has acquired Visudyne (verteporfin for injection), a drug-and-laser therapy which once represented a breakthrough therapy for wet age-related macular degeneration (AMD), from Canadian firm QLT. Valeant is paying $112.5 million up front and up to $20 million in milestones for all US rights and non-US royalties.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.